The stock of Craneware plc (LON:CRW) is a huge mover today! The stock decreased 1.37% or GBX 14 on November 29, hitting GBX 1011. About 250,664 shares traded hands or 957.56% up from the average. Craneware plc (LON:CRW) has risen 28.93% since May 2, 2016 and is uptrending. It has outperformed by 23.67% the S&P500.
The move comes after 6 months positive chart setup for the GBX 272.02 million company. It was reported on Nov, 29 by Barchart.com. We have GBX 1101.99 PT which if reached, will make LON:CRW worth GBX 24.48M more.
Craneware plc (LON:CRW) Ratings Coverage
Out of 3 analysts covering Craneware (LON:CRW), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Craneware has been the topic of 18 analyst reports since July 16, 2015 according to StockzIntelligence Inc. Investec maintained the stock with “Buy” rating in Wednesday, November 18 report. The firm earned “Buy” rating on Thursday, August 25 by Peel Hunt. The firm has “Buy” rating given on Monday, January 11 by Peel Hunt. The stock of Craneware plc (LON:CRW) has “Buy” rating given on Friday, January 22 by Peel Hunt. On Tuesday, September 6 the stock rating was maintained by Peel Hunt with “Buy”. As per Wednesday, July 6, the company rating was maintained by Peel Hunt. Peel Hunt maintained the stock with “Buy” rating in Tuesday, November 15 report. The stock of Craneware plc (LON:CRW) has “Buy” rating given on Thursday, November 10 by Peel Hunt. Investec maintained Craneware plc (LON:CRW) on Tuesday, September 8 with “Buy” rating. The rating was maintained by Investec on Tuesday, March 8 with “Buy”.
Craneware plc is a United Kingdom-based company, which is engaged in the development, licensing and ongoing support of computer software for the United States healthcare industry. The company has a market cap of 272.02 million GBP. The Company’s Value Cycle Solutions span over five product families, which include Patient Engagement, Charge Capture & Pricing, Coding Integrity, Cost Analytics, and Revenue Collection & Retention. It has a 32.42 P/E ratio. The Company’s Patient Engagement solutions include InSight Medical Necessity, Trisus Patient Payment and Patient Charge Estimator.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.